ProShare Advisors
IMNM icon

ProShare Advisors’s Immunome IMNM Stock Holding History

ProShare Advisors’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$324K Sell
14,799
-2,325
-14% -$51.7K ﹤0.01% 1294
2025
Q4 		$368K Buy
17,124
+3,930
+30% +$69K ﹤0.01% 1324
2025
Q3 		$155K Sell
13,194
-1,913
-13% -$19K ﹤0.01% 1758
2025
Q2 		$140K Sell
15,107
-241
-2% -$1.98K ﹤0.01% 1803
2025
Q1 		$103K Buy
15,348
+871
+6% +$8.36K ﹤0.01% 1828
2024
Q4 		$154K Buy
+14,477
New +$175K ﹤0.01% 1964

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

ProShare Advisors's IMNM Position: Q1 2026 in Review

ProShare Advisors reduced its Immunome (IMNM) stake by 14% in Q1 2026, selling an estimated $51.7K and leaving 14,799 shares worth $324K. The position accounts for ﹤0.01% of the portfolio, ranked #1294.

ProShare Advisors first reported a position in IMNM in Q4 2024 and has held it in 6 quarters since. The position peaked at $368K in Q4 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • ProShare Advisors held 14,799 shares of Immunome worth $324K as of Q1 2026.
  • ProShare Advisors sold 2,325 Immunome shares in Q1 2026, an estimated $51.7K.
  • Immunome made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1294 holding.
  • ProShare Advisors first reported a position in Immunome in Q4 2024 and has held it in 6 quarters since.
  • ProShare Advisors's Immunome position peaked at $368K in Q4 2025.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.